Ideas That Generate Results

Russian Pharma Sector Analysis

Russian Pharma Sector Analysis

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Sep, 2008| No. of Pages : 115

Share |
Please make your selection :
Electronic Access - Single User License
US$ 1100.00  550.00
CD-ROM Mail Delivery
US$ 1400.00  700.00
Hard Copy Mail Delivery
US$ 1400.00  700.00
Electronic Access - Multi-User License
US$ 1800.00  900.00

According to “Russian Pharma Sector Analysis”, the Russian pharmaceutical market grew at a slow pace in 2007 but it still is attractive as compared to previous years that recorded no-so-impressive performance due to the state segment. In the Russian pharma market, both the retail segment and parapharmaceutical market registered double-digit growth in sales value, with parapharmaceutical recording the highest growth rate and retail segment contributing the maximum share in sales value terms.

This research report provides an extensive research and objective analysis on the growing demand of pharmaceuticals in Russia and presents a clear picture of the country’s healthcare and pharmaceutical market. It covers Russian demographics, structure of healthcare sector, size and growth of pharmaceutical market, leading drugs, segment-wise break up, and information on major therapy areas to give strategic insight into the market. This report briefly discusses the major players operating in each segment of the market. The share of imported and domestic drugs, RX and OTC drugs, and sales structure by ATC group has also been analyzed in context of the Russian pharmaceutical market.

Key Research Findings

- The Russian pharmaceutical market grew 16% in 2007 as compared to 2006.
- State segment grew at a slower rate while the parapharmaceutical and commercial segments recorded impressive growth rates in 2007.
- In 2007, new drugs segment increased at fast pace as more than 230 new drug trade names appeared in the Russian pharmaceutical market. 
- In 2007, Sanofi-Aventis was the leader of the retail sales among the drug manufacturers in commercial drug market segment.
- The consumption value provided by the State Reimbursement Program (DLO) decreased in 2007 due to diminishing requirement.
- The Russian pharmaceutical market is forecasted to grow at a CAGR of 14.36% by 2012.

Key Issues Analyzed in the Report

- Where does the Russian pharmaceutical market stand in comparison to other key global markets?
- What is the market size of various segments in the Russian pharmaceutical industry?
- What is the proportion of domestic and imported drugs in each segment?
- What are the opportunities that will emerge in future for the market?
- Who are the major players in the Russian pharmaceutical market?

Research Methodology Used in the Report

Information Sources
The information in this report has been taken from various credible sources like books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

Analysis Methods
The analysis methods used in this report include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.

For the purpose of this report, the Russian pharmaceutical market has been considered to consist of the following segments:

- Commercial drugs market;
- State segment (DLO programme and Hospital Segment)
- Parapharmaceutical segment (Food Supplements and Cosmetics)

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.